Blood Coagulation Disorder clinical trials at University of California Health

3 in progress, 1 open to eligible people

Showing trials for

  • VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

    open to eligible people ages 12-60

    The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

    at UC Davis UCLA

  • Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

    Sorry, in progress, not accepting new patients

    This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.

    at UC Davis

  • Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

    Sorry, accepting new patients by invitation only

    The BMN 270 clinical development program consists of multiple interventional studies designed to assess the safety and efficacy of a single infusion of BMN 270 for at least 5 years post-infusion. This long-term follow-up study is needed to help further understand the long-term safety of BMN 270 beyond 5 years and to assess the durability of efficacy.

    at UC Davis

Last updated: